Abstract
Modern biology provides a plethora of experimental evidence that points to the chaotic and heterogenous nature of cancer, making it necessary to tackle each type of cancer as a unique problem in terms of treatment. The existence of a labyrinth of multiple backup networks for every biological event in the living cell, from membrane receptors and signal transduction proteins to cell cycle systems and DNA/RNA processing machinery, performs as a vicious snare when it comes to the treatment of cancer. Alternatively, the huge number of chemotherapeutic options available today, with all of their known and unknown pharmacological modes, presents another sort of chaos and heterogeneity. Taken together, the achievement of improved cancer therapy would be easier if we applied our modern knowledge of informatic sciences as a means of managing and matching the two sources of heterogeneity or chaos, i.e., cancer and chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Yamori, T. (1997) A human cell line panel for screening anticancer drugs. Jpn. J. Cancer Chemother. 24, 129–135.
Paull, K. D., Hamel, E. and Malspeis, L. (1995) Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute, in Cancer Chemotherapeutic Agents (Foye, W. O., ed.), American Chemical Society, Washington, D.C., pp. 9–45.
Monks, A., Scudiero, D., Skehan, P., et al. (1991) Feasibility of a high-flux drug screen using a diverse panel of cultured human tumour cell lines. J. Natl. Cancer Inst. 83, 757–766.
Weinstein, J. N., Myers, T. G., O’Connor, P. M., et al. (1997) An information intensive approach to the molecular pharmacology of cancer. Science 275, 343–349.
Paull, K. D., Shoemaker, R. H., Hodes, L., et al. (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. 81, 1088–1092.
Raymond, E., Sun, D., Chen, S.-F., Windle B., and Von Hoff, D. D. (1996) Agents that target telomase and telomeres. Curr. Opin. Biotechnol. 7, 583–591.
Blackburn, E. H. (1991) Structure and function of telomeres. Nature 350, 569–573.
Counter, C. M., Avilion, A. A., Le Feuvre, C. E., Stewart, N. G., Greider, C. W., Harley, C. B., and Bacchetti, S. (1992). Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 11, 1921–1929.
Wright, W. E., Brassiskyte, D., Piatyszek, M. A., and Shay, J. W. (1996) Experimental elongation of telomeres extends the life span of immortal x normal cell hybrids. EMBO J. 15, 1734–1741.
Koya, K., Lin, Y., Wang, H., et al. (1996) MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anti-carcinoma activity in preclinical studies based on selective mitochondrial accumulation. Cancer Res. 56, 538–543.
Naasani, I., Seimiya, H., Yamori, T., and Tsuruo, T. (1999) FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res. 59, 4004–4011.
Kawada, M., Uehara, Y., Mizuno, S., Yamori, T., and Tsuruo, T. (1998) Up-regulation of p27kip1 correlates inversely with anchorage independent growth of human cancer cell lines. Jpn. J. Cancer Res. 89, 110–115.
Rubenstein, L.V., Shoemaker, R. H., Paull, K. D., et al. (1990) Comparison of in vitro anti-cancer drug screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst. 82, 1113–1118.
Kim, N. W., Piatyszek, M. A., Prowse, K. R., et al. (1994) Specific association of human telomerase activity with immortal cells and cancer. Science. 266, 2011–2015.
Naasani, I., Seimiya, H., and Tsuruo, T. (1998) Telomerase inhibition, telomere shortening and senescence of cancer cells by tea catechins. Biochem. Biophys. Res. Commun. 19, 391–396.
Wright, W. E., Shay, J. W., and Piatyszek, M. A. (1995) Modifications of a telomeric repeat amplification protocol (TRAP) result in in creased reliability, linearity and sensitivity. Nucleic Acids Res. 23, 3794–3795.
Krupp, G., Kuhne, K., Tamm, S., Klapper, W., Heidorn, K., Rott, A. and Parwaresch, R. (1997) Molecular basis of artifacts in the detection of telomerase activity and a modified primer for a more robust TRAP assay. Nucleic Acids Res. 25, 919–921.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Naasani, I., Yamori, T., Tsuruo, T. (2002). Screening with COMPARE Analysis forTelomerase Inhibitors. In: Double, J.A., Thompson, M.J. (eds) Telomeres and Telomerase. Methods in Molecular Biology™, vol 191. Humana Press. https://doi.org/10.1385/1-59259-189-2:197
Download citation
DOI: https://doi.org/10.1385/1-59259-189-2:197
Publisher Name: Humana Press
Print ISBN: 978-0-89603-657-4
Online ISBN: 978-1-59259-189-3
eBook Packages: Springer Protocols